Corrigendum: Immune Phenotyping of Patients With Acute Vogt-Koyanagi-Harada Syndrome Before and After Glucocorticoids Therapy

Jiang, Han; Li, Zhaohui; Yu, Long; Zhang, Ying; Zhou, Li; Wu, Jing; Yuan, Jing; Han, Mengyao; Xu, Tao; He, Junwen; Wang, Shan; Yu, Chang; Pan, Sha; Wu, Min; Liu, Hangyu; Zeng, Hongtao; Song, Zhu; Wang, Qiangqiang; Qu, Shen; Zhang, Junwei; Huang, Yafei; Han, Junyan

doi:10.3389/fimmu.2021.731824

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the clinical findings and laboratory data, she was diagnosed with incomplete VKH disease due to the presence of ocular signs and neurological findings 4 . Early and aggressive systemic glucocorticosteroid therapy remains the primary treatment according to the standard treatment for VKH disease 5 . The patient was treated with pulse intravenous methylprednisolone therapy (1000 mg/day) followed by a subsequent high‐dose oral corticosteroid regimen upon confirmation of the VKH disease diagnosis.…”

Section: Case Reportmentioning

confidence: 99%

Vogt–Koyanagi–Harada disease after SARS‐CoV‐2 infection: Case report and literature review

Zou,

Zhang,

Chen

et al. 2024

Immunity Inflam & Disease

View full text Add to dashboard Cite

BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is responsible for coronavirus disease 2019 (COVID‐19), a complex and multifaceted illness. COVID‐19 is associated with various ocular manifestations including conjunctivitis, retinal vein occlusion and optic neuritis. However, the case of Vogt‐Koyanagi‐Harada (VKH) disease associated with SARS‐CoV‐2 is infrequent, and the specific association is still unclear.Case PresentationIn the present study, a 35‐year‐old female patient without any significant medical history presented with 1 week of bilateral blurred vision, occurring 2 weeks after a clinical course of COVID‐19. Upon examination, both eyes exhibited bullous serous retinal detachments. She was diagnosed with incomplete VKH disease. Early diagnosis and treatment of VKH disease are essential for the visual prognosis of this aggressive disease. In this particular patient, ocular inflammatory signs and visual acuity improved via corticosteroid therapy. It is worth noting that the occurrence of VKH disease associated with SARS‐CoV‐2 is uncommon, and the specific connection between the two remains unknown. We review and summarize the clinical characteristics of VKH disease following SARS‐CoV‐2 infection, and discuss the potential mechanisms that may explain this phenomenon, based on similar studies previously reported.ConclusionDespite the unclear causality, it is important for ophthalmologists and physicians to be recognizant of the possible association between VKH disease and COVID‐19. SARS‐CoV‐2 may play a potential immunological triggering role in VKH disease. However, further in‐depth research is necessary to investigate the clinical and epidemiological features, as well as the underlying mechanisms of this association.

show abstract

Section: Case Reportmentioning

confidence: 99%